Intravenous Immunoglobulin (IVIG) from Octapharma USA.
Panzyga is a 10% IVIG product from Octapharma with broad approved indications including primary humoral immunodeficiency, chronic ITP, and CIDP. Its formulation supports flexible infusion protocols.
Panzyga is FDA-approved for the following indications:
Panzyga is administered intravenously every three to four weeks. Infusion site options are the same as other IVIG products.
The manufacturer offers a patient support program — Octapharma Patient Resources — that can help with insurance navigation, copay assistance for eligible patients, nursing support, and ongoing education. More information is available at https://www.octapharma.com/us/patients.
Treatment with Panzyga is initiated and monitored by Dr. McNeil. Prior authorizations are handled in-house — patients are not asked to navigate insurance approvals on their own. Infusion logistics are coordinated through trusted partner infusion providers — including Horizon Infusions, where the practice is co-located — or arranged for home infusion when appropriate. The team handles scheduling, nursing coordination, and prior-authorization renewals.
Important safety note: This page is not a substitute for the FDA prescribing information. Risks, contraindications, drug interactions, and required monitoring vary by patient. The official manufacturer website (https://www.panzyga.com) provides the most current full prescribing and safety information. Treatment decisions and monitoring are individualized — please discuss with Dr. McNeil whether Panzyga is appropriate for your situation.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes only and is not medical advice. If you have an emergency, call 911.